Argenx Se (ARGX) Gets a Buy Rating from Stifel Nicolaus


In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Argenx Se (ARGX), with a price target of $154. The company’s shares opened today at $122.08.

Archila said:

“We are reiterating our Buy rating on shares and $154 target price as we continue to view ARGX’s efgartigimod as best positioned among the candidates in the FcRn class given: (1) it has first-mover advantage; (2) the fact it already has a verified subcutaneous (SC) injectable presentation; and (3) it has generated proof-of-concept data in three indications (gMG, ITP and PV) with a solid safety profile. One interesting update in the PR was the company potentially plans to run its Phase 3 study for efgartigimod in ITP using both IV and SC formulations which could expedite the latter’s path to market. Looking ahead, we don’t see the upcoming 2019 as a major catalyst but expect it to be quite informative in that we expect management to discuss leveraging their antibody platform for future development programs and two new antibody candidates and their biologic rationale.”

According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.2% and a 33.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Principia Biopharma Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $151.67 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $135.58 and a one-year low of $63.81. Currently, Argenx Se has an average volume of 162.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts